Yarrow Bioscience stock fell 8.85 percent on October 5, 2026

Published on 10/05/2026 at 23:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Yarrow Bioscience stock fell to USD 20.30 on October 5, 2026, after the company raised USD 172.5 million in September. Analysts list a USD 57 target.

YARW, US92941V4077, Illustration mit AI erstellt.

Yarrow Bioscience stock (ISIN US92941V4077) was last at USD 20.30 on Nasdaq on October 5, 2026 at 4:00 p.m. ET, down 8.85 percent from USD 22.27. The move followed a USD 172.5 million financing completed in September as the clinical-stage biotechnology company funds its autoimmune thyroid disease pipeline.

Financing adds clinical runway

On September 14, 2026, Business Wire reported that Yarrow had closed an underwritten offering of 6,634,615 shares at USD 26.00 each. The transaction included the full exercise of an option for 865,384 additional shares and generated USD 172.5 million in gross proceeds.

Yarrow said the proceeds would support research and development, working capital and other corporate purposes, according to Business Wire. That financing gives the company a larger cash base, but the additional shares also leave investors focused on clinical execution and dilution.

Revenue remains small in Q2

Tickertape lists Q2 2026 revenue at USD 0.09 million, up from USD 0.08 million in Q1 2026, a 12.5 percent increase. Net income was negative USD 3.0 million in Q2 versus negative USD 3.58 million in Q1, while the company remains centered on development rather than commercial sales.

Yarrow is developing YB-101, an anti-thyroid stimulating hormone receptor antibody aimed at Graves' disease and thyroid eye disease, according to Business Wire. The candidate is being evaluated in a Phase 2a/2b program, making clinical data the central value driver for the company.

Consensus target stands above the stock

MarketScreener lists a Buy consensus from 3 analysts and an average price target of USD 57.00. That target lies 180.79 percent above the October 5 price, a wide gap that reflects the market's dependence on development milestones rather than established product revenue.

Stock remains below yearly high

Yarrow Bioscience stock was last at USD 20.30 on Nasdaq on October 5, 2026 at 4:00 p.m. ET, with volume of 102,502 shares and market capitalization of USD 188.9 million. The price stood 56.76 percent below its 52-week high of USD 46.95 and above the 52-week low of USD 16.04.